Coronary Atherosclerosis of Native Coronary ArteryNCT07074847
Coronary Arterial Microcirculation and Metabolism
An observational study of Coronary Atherosclerosis of Native Coronary Artery, run by Shaanxi Provincial People's Hospital at 1 site in China.
Trial summary
Coronary microcirculation disorder refers to a disease in which small blood vessels in the coronary arteries are damaged or blocked, leading to myocardial ischemia and hypoxia. This disease usually occurs in patients with coronary heart disease, but it can also occur in other populations. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Coronary Atherosclerosis of Native Coronary Artery
- What is being tested?
- Measure QFR
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 28 Feb 2025to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: Patients with normal coronary angiography or stenosis less than 50%
Who may be able to join
- Patients with normal coronary angiography or stenosis less than 50%
Who cannot join
- Coronary angiography indicates patients with coronary stenosis greater than 50%.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Department of Cardiology, Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, 710068
About this study
Coronary microcirculation disorder refers to a disease in which small blood vessels in the coronary arteries are damaged or blocked, leading to myocardial ischemia and hypoxia. This disease usually occurs in patients with coronary heart disease, but it can also occur in other populations. It is caused by abnormal endothelial function of coronary arteries or spasm of small arteries. Its symptoms include chest pain, shortness of breath, palpitations, etc., which usually occur during physical activity or emotional excitement. If left untreated, it may lead to serious consequences such as myocardial infarction.
The methods for treating coronary microcirculation disorders include drug therapy, surgical treatment, and lifestyle changes. Drug therapy includes antiplatelet drugs, lipid-lowering drugs, vasodilators, etc; Surgical treatment includes coronary artery bypass grafting and percutaneous coronary intervention. Lifestyle changes include quitting smoking, weight control, and increasing physical activity. In summary, coronary microcirculation disorders are a disease that leads to myocardial ischemia and require sufficient attention. Early detection and effective treatment measures can prevent the occurrence of complications and improve the quality of life.
If patients with coronary microcirculation disorders can be detected early and treated accordingly, serious consequences can be avoided. Therefore, we plan to investigate the correlation between coronary microcirculation and metabolomics, with the aim of identifying metabolites closely related to coronary microcirculation from the perspective of metabolomics, in order to elucidate the metabolic processes involved in coronary microcirculation disorders.
- Being tested
- Measure QFR
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Measure QFROther
Collect blood samples from 100 patients with normal coronary angiography or stenosis less than 50%, centrifuge and collect plasma, and then send them for further metabolomics testing to analyze the test results.
What is being measured
The primary outcome is the main question the study is designed to answer.
Microcirculatory resistance index
Measured: 2025.2.28-2025.12.31
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2025
- Study start28 Feb 2025
- Primary completion30 Oct 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Atherosclerosis of Native Coronary ArteryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shaanxi Provincial People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07074847
- Sponsor's protocol ID
- SPPH-311-320
- Status last verified
- Jul 2025
- First submitted
- 10 Jul 2025
- Last updated
- 20 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Coronary Arterial Microcirculation and Metabolism
- ClinicalTrials.gov ID
- NCT07074847
- Acronym / sponsor ID
- SPPH-311-320
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Shaanxi Provincial People's HospitalUniversity, hospital or other
- Study start
- 28 Feb 2025 (actual)
- Primary completion
- 30 Oct 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 20 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Coronary microcirculation disorder refers to a disease in which small blood vessels in the coronary arteries are damaged or blocked, leading to myocardial ischemia and hypoxia. This disease usually occurs in patients with coronary heart disease, but it can also occur in other populations. It is caused by abnormal endothelial function of coronary arteries or spasm of small arteries. Its symptoms include chest pain, shortness of breath, palpitations, etc., which usually occur during physical activity or emotional excitement. If left untreated, it may lead to serious consequences such as myocardial infarction.
The methods for treating coronary microcirculation disorders include drug therapy, surgical treatment, and lifestyle changes. Drug therapy includes antiplatelet drugs, lipid-lowering drugs, vasodilators, etc; Surgical treatment includes coronary artery bypass grafting and percutaneous coronary intervention. Lifestyle changes include quitting smoking, weight control, and increasing physical activity. In summary, coronary microcirculation disorders are a disease that leads to myocardial ischemia and require sufficient attention. Early detection and effective treatment measures can prevent the occurrence of complications and improve the quality of life.
If patients with coronary microcirculation disorders can be detected early and treated accordingly, serious consequences can be avoided. Therefore, we plan to investigate the correlation between coronary microcirculation and metabolomics, with the aim of identifying metabolites closely related to coronary microcirculation from the perspective of metabolomics, in order to elucidate the metabolic processes involved in coronary microcirculation disorders.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with normal coronary angiography or stenosis less than 50%
Key inclusion criteria (1 listed)
- Patients with normal coronary angiography or stenosis less than 50%
Key exclusion criteria (1 listed)
- Coronary angiography indicates patients with coronary stenosis greater than 50%.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Measure QFRCollect blood samples from 100 patients with normal coronary angiography or stenosis less than 50%, centrifuge and collect plasma, and then send them for further metabolomics testing to analyze the test results. | Other | – |
Primary outcome
Microcirculatory resistance index
Time frame: 2025.2.28-2025.12.31
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2025.
- Individual participant dataSharing planned: Yes
Related trials for Coronary Atherosclerosis of Native Coronary Artery
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Atherosclerosis of Native Coronary Artery, run by Shaanxi Provincial People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 20 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Microcirculatory resistance index (time frame: 2025.2.28-2025.12.31). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2025; AzTrials last refreshed its copy on 7 Nov 2026.